Aardvark Therapeutics Shareholders Face October Deadline in Fraud Suit
Investors who incurred financial losses tied to Aardvark Therapeutics now have until October 13, 2026, to file as lead plaintiffs in a pending securities fraud class action. The litigation centers on allegations that the company misled stakeholders regarding the safety and commercial viability of its drug candidate, ARD-101.
The complaint, filed by the Law Offices of Frank R. Cruz, contends that Aardvark Therapeutics issued materially false statements between February 10, 2025, and May 14, 2026. According to the filing, the company failed to disclose that ARD-101 possessed a lower safety profile than publicly represented. These omissions allegedly led to an overstatement of the drug’s regulatory and clinical prospects, resulting in financial harm to shareholders once the reality of the situation surfaced.
Parties interested in the case may contact the firm at 310-914-5007 or via email to evaluate their legal standing. While the deadline for seeking lead plaintiff status is October 13, investors are not required to take immediate action to remain members of the class. Those who choose to participate may either retain their own counsel or rely on the lead plaintiff to represent their interests in the ongoing proceedings.
Comments (0)
No comments yet. Be the first!